Open access · CC-BY
via OpenAlex
Rapamycin-induced metabolic defects are reversible in both lean and obese mice
Yuhong Liu, Vivian Diaz, Elizabeth Fernández, Randy Strong, Lan Ye, Joseph A. Baur, Dudley W. Lamming, Arlan G Richardson, Adam B. Salmon
Aging · 2014 · ▲ 68 citations
Abstract
The inhibition of mTOR(definition) (mechanistic target of rapamycin(definition)) by the macrolide rapamycin has many beneficial effects in mice, including extension of lifespan and reduction or prevention of several age-related diseases. At the same time, chronic rapamycin treatment causes impairments in glucose metabolism including hyperglycemia, glucose intolerance and insulin resistance. It is unknown whether these metabolic effects of rapamycin are permanent or whether they can be alleviated. Here, we confirmed that rapamycin causes glucose intolerance and insulin resistance in both inbred and genetically heterogeneous mice fed either low fat or high fat diets, suggesting that these effects of rapamycin are independent of genetic background. Importantly, we also found that these effects were almost completely lost within a few weeks of cessation of treatment, showing that chronic rapamycin treatment does not induce permanent impairment of glucose metabolism. Somewhat surprisingly, chronic rapamycin also promoted increased accumulation of adipose tissue in high fat fed mice. However, this effect too was lost when rapamycin treatment was ended suggesting that this effect of rapamycin is also not permanent. The reversible nature of rapamycin's alterations of metabolic function suggests that these potentially detrimental side-effects might be managed through alternative dosing strategies or concurrent treatment options.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18632/aging.100688
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Liu, Y., Diaz, V., Fernández, E., Strong, R., Ye, L., Baur, J.A., Lamming, D.W., Richardson, A.G., & Salmon, A.B. (2014). Rapamycin-induced metabolic defects are reversible in both lean and obese mice. <em>Aging</em>. https://doi.org/10.18632/aging.100688
Vancouver
Liu Y, Diaz V, Fernández E, Strong R, Ye L, Baur JA, et al. Rapamycin-induced metabolic defects are reversible in both lean and obese mice. Aging. 2014. doi:10.18632/aging.100688.
BibTeX
@article{yuhong2014Rapamy,
title = {Rapamycin-induced metabolic defects are reversible in both lean and obese mice},
author = {Yuhong Liu and Vivian Diaz and Elizabeth Fernández and Randy Strong and Lan Ye and Joseph A. Baur and Dudley W. Lamming and Arlan G Richardson and Adam B. Salmon},
journal = {Aging},
year = {2014},
doi = {10.18632/aging.100688},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging 2014
Open access · OA
Rapamycin in preventive (very low) doses
Aging Pathobiology and Therapeutics 2020
Open access · CC-BY
Sex-dependent lifespan extension of ApcMin/+ FAP mice by chronic mTOR inhibition
Oncotarget 2015
Open access · OA
About-face on the metabolic side effects of rapamycin
cIRcle (University of British Columbia) 2015
Preprint · CC-BY
Caloric restriction in the context of reduced insulin
Oxidative Medicine and Cellular Longevity 2018
Open access · CC-BY
mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?
Aging Cell 2015
Open access · CC-BY